Success Metrics

Clinical Success Rate
100.0%

Based on 17 completed trials

Completion Rate
100%(17/17)
Active Trials
0(0%)
Results Posted
41%(7 trials)

Phase Distribution

Ph phase_1
2
11%
Ph phase_2
7
37%
Ph phase_4
7
37%
Ph not_applicable
1
5%
Ph phase_3
1
5%

Phase Distribution

2

Early Stage

7

Mid Stage

8

Late Stage

Phase Distribution18 total trials
Phase 1Safety & dosage
2(11.1%)
Phase 2Efficacy & side effects
7(38.9%)
Phase 3Large-scale testing
1(5.6%)
Phase 4Post-market surveillance
7(38.9%)
N/ANon-phased studies
1(5.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

89.5%

17 of 19 finished

Non-Completion Rate

10.5%

2 ended early

Currently Active

0

trials recruiting

Total Trials

19

all time

Status Distribution
Completed(17)
Terminated(2)

Detailed Status

Completed17
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
19
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (11.1%)
Phase 27 (38.9%)
Phase 31 (5.6%)
Phase 47 (38.9%)
N/A1 (5.6%)

Trials by Status

completed1789%
withdrawn211%

Recent Activity

0 active trials
Showing 5 of 19
completedphase_4

A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)

NCT01429792
completedphase_2

A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C

NCT01903954
completedphase_2

A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis

NCT01749150
completedphase_2

A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4

NCT01057667
withdrawnphase_2

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment

NCT01579019
View all 19 trials

Clinical Trials (19)

Showing 19 of 19 trials
NCT01429792Phase 4

A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)

Completed
NCT01903954Phase 2

A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C

Completed
NCT01749150Phase 2

A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis

Completed
NCT01057667Phase 2

A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4

Completed
NCT01579019Phase 2

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment

Withdrawn
NCT01296971Phase 3

A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)

Withdrawn
NCT01278134Phase 2

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)

Completed
NCT01591460Phase 4

A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C

Completed
NCT01697436Phase 1

A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets

Completed
NCT01628094Phase 2

ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment

Completed
NCT01615393Phase 1

A Study to Compare the Bioavailability of Copegus and Vilona® in Healthy Volunteers

Completed
NCT01447420Phase 4

A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)

Completed
NCT00700401

POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).

Completed
NCT00077649Phase 4

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).

Completed
NCT01585324Phase 4

A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)

Completed
NCT00910975Phase 4

Individualized Duration of Peg-interferon/Ribavirin Treatment of Hepatitis C

Completed
NCT00545233Phase 4

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.

Completed
NCT00909129Not Applicable

Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment

Completed
NCT00088504Phase 2

Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C

Completed

All 19 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
19